Diagnosis, Evaluation, Prevention and Treatment of CKD-MBDAbdullah Ansari
Introduction and definition of CKD–MBD
Diagnosis of CKD–MBD: biochemical abnormalities
Diagnosis of CKD–MBD: bone
Diagnosis of CKD–MBD: vascular calcification
Treatment of CKD–MBD targeted at serum phosphorus and serum calcium
Treatment of abnormal PTH levels in CKD–MBD
Treatment of bone with bisphosphonates, other osteoporosis medications and growth hormone
Evaluation and treatment of kidney transplant bone disease
Diagnosis, Evaluation, Prevention and Treatment of CKD-MBDAbdullah Ansari
Introduction and definition of CKD–MBD
Diagnosis of CKD–MBD: biochemical abnormalities
Diagnosis of CKD–MBD: bone
Diagnosis of CKD–MBD: vascular calcification
Treatment of CKD–MBD targeted at serum phosphorus and serum calcium
Treatment of abnormal PTH levels in CKD–MBD
Treatment of bone with bisphosphonates, other osteoporosis medications and growth hormone
Evaluation and treatment of kidney transplant bone disease
- Recorded videos of this lecture:
English Language version of this lecture is available at:
https://youtu.be/AtiaKPIdzAQ
Arabic Language version of this lecture is available at:
https://youtu.be/2cwyPcRDGEY
- Visit our website for more lectures: www.NephroTube.com
- Subscribe to our YouTube channel: www.youtube.com/NephroTube
- Join our facebook group: www.facebook.com/groups/NephroTube
- Like our facebook page: www.facebook.com/NephroTube
- Follow us on twitter: www.twitter.com/NephroTube
Chapter 12 Chronic Kidney Disease and DialysisKalvinSmith4
For DH Theory III, students must give a presentation on a specific module in the class. The purpose of these presentations is to inform students on how treat patients in a dental setting who may be compromised by a certain medical condition. I was tasked with presenting on chronic kidney disease and dialysis, as well as on sexually transmitted diseases. This is the presentation that I modified on CKD and dialysis.
- Recorded videos of this lecture:
English Language version of this lecture is available at:
https://youtu.be/AtiaKPIdzAQ
Arabic Language version of this lecture is available at:
https://youtu.be/2cwyPcRDGEY
- Visit our website for more lectures: www.NephroTube.com
- Subscribe to our YouTube channel: www.youtube.com/NephroTube
- Join our facebook group: www.facebook.com/groups/NephroTube
- Like our facebook page: www.facebook.com/NephroTube
- Follow us on twitter: www.twitter.com/NephroTube
Chapter 12 Chronic Kidney Disease and DialysisKalvinSmith4
For DH Theory III, students must give a presentation on a specific module in the class. The purpose of these presentations is to inform students on how treat patients in a dental setting who may be compromised by a certain medical condition. I was tasked with presenting on chronic kidney disease and dialysis, as well as on sexually transmitted diseases. This is the presentation that I modified on CKD and dialysis.
chronic kidney failure definition and stages of "CKD" SOAP (subjective,objective,assessment and planing ) example format to easy understand about CKD patients.
Introduction to Chronic Kidney Disease epidemiology, diagnosis, treatment of complications and system issues (e.g. interface between nephrology and primary care, specialty referrals) for medical students
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
2. 0
5
10
15
20
25
30
35
1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996
Year of ESRD Incidence or Transplantation
21.5
19.8
4.1
2.0
1999 annual report of the US Renal Data System
Deaths/100patient
Dialysis All ESRD Cadaveric Transplant Living Related Transplant
Adjusted 1st Year Patient Death Rates by Treatment
Modality and Year of Incidence, 1986-96
Brought to you by
3. 0.01
100
10
1
0.1
Annualmortality(%)
25–34 45–54 65–74 ≥8535–44 55–64 75–84
Age (years)
Cardiovascular Mortality in the General Population
and in Dialysis Patients
General population
Male
Female
Black
White
Dialysis population
Male
Female
Black
White
Brought to you by
4. NKF’s Clinical Practice Guidelines
• Evidence Based Review
• Publication and Dissemination
• Implementation
• Reassess Impact
• Update
Brought to you by
5. DOQI KDIGOK/DOQI
Dialysis
Anemia
Access
Nutrition (00)
Dialysis (’01)*
Anemia (’01)*
Access(‘01)*
CKD class. (’02)
Bone/Mineral (’03)
Lipids (’03)
Htn (’04)
CV (’05)
Diabetes (’07)
Hep C (’08)
Bone/Mineral (’08)
1997 2005
*updates
http://www.kidney.org/professionals/kdoqi
1999
http://www.kdigo.org/welcome.htm
Brought to you by
6. NKF-K/DOQI Definition of CKD
Structural or functional abnormalities of the kidneys
for >3 months, as manifested by either:
1. Kidney damage, with or without decreased GFR,
as defined by
• pathologic abnormalities
• markers of kidney damage
– urinary abnormalities (proteinuria)
– blood abnormalities (renal tubular syndromes)
– imaging abnormalities
• kidney transplantation
2. GFR <60 ml/min/1.73 m2
, with or without kidney
damage Brought to you by
7. Stage Description GFR
(ml/min/1.73 m2
)
1 Kidney damage with normal or ↑
GFR
≥ 90
2 Kidney damage with mild ↓ GFR 60-89
3 Moderate ↓ GFR 30-59
4 Severe ↓ GFR 15-29
5 Kidney failure < 15
(or dialysis)
KDOQI: CKD Staging
Brought to you by
8. CKD is a Public Health Problem
• CKD is common
• CKD is harmful
• We have treatment
Brought to you by
9. CKDCKD
deathdeath
CKDCKD
deathdeath
ComplicationsComplicationsComplicationsComplications
Screening
for CKD
risk factors:
diabetes
hypertension
age >60
family history
US ethnic
minorities
CKD risk
reduction;
Screening for
CKD
Diagnosis
& treatment;
Treat
comorbid
conditions;
Slow
progression
Estimate
progression;
Treat
complications;
Prepare for
replacement
Replacement
by dialysis
& transplant
NormalNormalNormalNormal
IncreasedIncreased
riskrisk
IncreasedIncreased
riskrisk
KidneyKidney
failurefailure
KidneyKidney
failurefailure
DamageDamageDamageDamage ↓↓ GFRGFR↓↓ GFRGFR
11.3 m11.3 m
5.6%5.6%
7.7 m7.7 m7.7 m7.7 m
3.8%3.8%
0.3 m0.3 m
0.2%0.2%
Conceptual Model for CKD
Brought to you by
10. KI (2007) 71, 31-38. Levin et. al.
Prevalence of Abnormal Mineral Metabolism in CKD
>4.6
Brought to you by
11. K/DOQI Clinical Practice Guidelines
on Bone Metabolism and Disease
in Chronic Kidney Disease
Published October 2003
Brought to you by
12. KDOQI Clinical Practice Guidelines for Bone Metabolism
and Disease in Chronic Kidney Disease
Chair: Vice-Chair:
Shaul G. Massry, MD Jack W. Coburn, MD
KECK School of Medicine VA Greater Los Angeles
Work Group Members:
Glenn M. Chertow, MD, MPH James T. McCarthy, MD
University of California, San Francisco Mayo Clinic
Keith Hruska, MD Sharon Moe, MD
Barnes Jewish Hospital Indiana University
Craig Langman, MD Isidro B. Salusky, MD
Children’s Memorial Hospital UCLA School of Medicine
Hartmut Malluche, MD Donald J. Sherrard, MD
University of Kentucky VA Puget Sound
Kevin Martin, MD, BCh Miroslaw Smogorzewski, MD
St. Louis University University of Southern California
Linda M. McCann, RD, CSR, LD Kline Bolton, MD
Satellite Dialysis Centers RPA Liaison
Brought to you by
13. K/DOQI™ Clinical Practice Guidelines
on Bone Metabolism Target Levels
CKD
Stage 3
CKD
Stage 4
CKD
Stage 5
(on dialysis)
P
(mg/dL)
2.7 - 4.6 2.7 - 4.6 3.5 - 5.5*
Ca
(mg/dL)
“Normal” “Normal”
8.4 - 9.5;
Hypercalcemia =
>10.2
Intact
PTH
(pg/mL)
35 - 70 70 - 110
150 - 300*
*Evidence Brought to you by
14. Treatment Recommendations
(Stages 3 & 4)
• Decrease total body phosphorus burden by dietary
restriction and phosphorus binder therapy- 2.7- 4.6
mg/dL; begin when EITHER elevated serum
phosphorus OR elevated serum PTH
• Treat elevated PTH with active oral vitamin D sterol
to target of 35-70 (CKD 3) or 70-110 (CKD 4) pg/mL
by intact assay
• Normalize serum calcium
Brought to you by
15. • Normalize serum phosphorus by diet and
phosphorus binder therapy- 3.5-5.5 mg/dL
(1.13 -1.78 mmol/L); limit elemental calcium
intake from binders to 1500 mg/day
• Treat elevated PTH with active vitamin D sterol
to target of 150-300 pg/mL (16-32 pmol/L) by
intact assay
• Normalize serum calcium- ideally 8.4 -9.5
mg/dL (2.10-2.38 mmol/L), and always < 10.2
mg/dL (2.55 mmol/L); Ca X P < 55 mg2
/dL2
Treatment Recommendations
Stage 5 (dialysis)
Brought to you by
16. Abnormal boneAbnormal bone
AgeAge
Oxidation (OxLDL)Oxidation (OxLDL)
DiabetesDiabetes
HTNHTN
Advanced glycationAdvanced glycation
end-productsend-products
SmokingSmoking
GeneticsGenetics
DyslipidemiaDyslipidemia
Carbonyl stressCarbonyl stress
Low fetuin-ALow fetuin-A
Traditional Risk Factors Non-traditional Risk Factors
Elevated IL-1, Il-6, TNFElevated IL-1, Il-6, TNFαα
HomocysteineHomocysteine
Abnormal mineral metabolismAbnormal mineral metabolism
FracturesFractures
CardiovascularCardiovascular
disease in CKDdisease in CKD
Brought to you by
17. Classification Issues in
Bone and Mineral Disorders
• The term renal osteodystrophy is used to
describe different entities
• The predominant use is to describe a disorder of
bone remodeling. However this does not take
into account new data that there is increased
morbidity/mortality of abnormal serum
biochemistries (i.e. phosphorus), nor increased
awareness of vascular disease related to bone
and mineral disorders in CKD patients.
Brought to you by
18. Definition, Evaluation and Classification
of Renal Osteodystrophy:
A position statement from Kidney Disease
Improving Global Outcomes (KDIGO)
April, 2006
Brought to you by
19. Standardization of Terms
• The term renal osteodystrophy (ROD) should
be used exclusively to define the bone
pathology associated with CKD.
• The clinical, biochemical, and imaging
abnormalities should be defined more broadly
as a clinical entity or syndrome called Chronic
Kidney Disease-Mineral and Bone Disorder
(CKD-MBD).
20. Definition of CKD-MBD
A systemic disorder of mineral and bone
metabolism due to CKD manifested by
either one or a combination of the
following:
– Abnormalities of calcium, phosphorus, PTH, or
vitamin D metabolism
– Abnormalities in bone turnover, mineralization,
volume, linear growth, or strength
– Vascular or other soft tissue calcification
Moe et al Kidney International June 2006
21. A Framework for Classification of CKD-MBD
Type*
Laboratory
Abnormalities
Bone Disease
Calcification of
Vascular or Other
Soft Tissue
L + - -
LB + + -
LC + - +
LBC + + +
* L = laboratory abnormalities (of calcium, phosphorus, PTH,
alkaline phosphatase or vitamin D metabolism); B = bone disease
(abnormalities in bone turnover, mineralization, volume, linear
growth, or strength); C = calcification of vascular or other soft
tissue.
Kidney International June 2006
23. Summary
1. CKD is defined using eGFR and classified into 5
stages
2. This classification can help predict clinical outcomes
3. Early detection and treatment can improve patient
outcomes
4. There is a link between CVD and bone and mineral
disease in CKD
5. New CKD-MBD classification will form the basis for
updated, international clinical practice guidelines
Brought to you by
24. Population Attributable Risk of All
Cause Mortality in CKD 5D
• 17.5% Mineral metabolism abnormalities
(Phosphorus > 5.0 mg/dl, Calcium >
10 mg/dl, intact PTH > 600 pg/ml)
• 11.3% Anemia (hgb < 11 g/dl)
• 5.1% Inefficient Dialysis (URR < 65%)
Corollary: We should be able to significantly
improve mortality of CKD patients by improving
control of mineral metabolism Brought to you by